NO20002787L - New connections - Google Patents

New connections

Info

Publication number
NO20002787L
NO20002787L NO20002787A NO20002787A NO20002787L NO 20002787 L NO20002787 L NO 20002787L NO 20002787 A NO20002787 A NO 20002787A NO 20002787 A NO20002787 A NO 20002787A NO 20002787 L NO20002787 L NO 20002787L
Authority
NO
Norway
Prior art keywords
new connections
preparation
pharmaceutical compositions
therapy
connections
Prior art date
Application number
NO20002787A
Other languages
Norwegian (no)
Other versions
NO20002787D0 (en
Inventor
Andrew Baxter
David Cheshire
Thomas Mcinally
Michael Mortimore
David Cladingboel
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20002787D0 publication Critical patent/NO20002787D0/en
Publication of NO20002787L publication Critical patent/NO20002787L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet nye forbindelser, en fremgangsmåte for fremstilling derav, farmasøytiske blandinger som inneholder disse og en fremgangsmåte for fremstilling av de farmasøytiske sammensetningene og deres bruk i terapi.There are disclosed novel compounds, a process for their preparation, pharmaceutical compositions containing them and a process for the preparation of the pharmaceutical compositions and their use in therapy.

NO20002787A 1997-12-05 2000-05-31 New connections NO20002787L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704546A SE9704546D0 (en) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002190 WO1999029686A1 (en) 1997-12-05 1998-12-01 Novel compounds

Publications (2)

Publication Number Publication Date
NO20002787D0 NO20002787D0 (en) 2000-05-31
NO20002787L true NO20002787L (en) 2000-08-01

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002787A NO20002787L (en) 1997-12-05 2000-05-31 New connections

Country Status (16)

Country Link
EP (1) EP1037889A1 (en)
JP (1) JP2001525406A (en)
KR (1) KR20010032800A (en)
CN (1) CN1284074A (en)
AU (1) AU1791599A (en)
BR (1) BR9813378A (en)
CA (1) CA2312357A1 (en)
EE (1) EE200000321A (en)
HU (1) HUP0100731A3 (en)
IL (1) IL136368A0 (en)
NO (1) NO20002787L (en)
PL (1) PL340837A1 (en)
SE (1) SE9704546D0 (en)
SK (1) SK8442000A3 (en)
TR (1) TR200001544T2 (en)
WO (1) WO1999029686A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901875D0 (en) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (en) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
JP2002330787A (en) * 2000-10-21 2002-11-19 Astrazeneca Ab Chemical substance
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
ATE355273T1 (en) 2003-05-12 2006-03-15 Pfizer Prod Inc BENZAMIDINE INHIBITORS OF THE P2X7 RECEPTOR
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
WO2006003500A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
DK2001474T3 (en) 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
MX2009000117A (en) * 2006-07-06 2009-01-23 Glaxo Group Ltd Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use.
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
JP2010520875A (en) 2007-03-09 2010-06-17 レノビス， インコーポレイテッド Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP2139858A1 (en) * 2007-03-28 2010-01-06 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
WO2008119685A2 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
MX2009010759A (en) * 2007-04-03 2009-10-28 Glaxo Group Ltd Imidazolidine carboxamide derivatives as p2x7 modulators.
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
BRPI0910034B1 (en) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag P2X7R ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THAT COMPRISE THEM
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
SG185400A1 (en) 2010-05-14 2012-12-28 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2019102354A1 (en) 2017-11-21 2019-05-31 3M Innovative Properties Company Oral plant-based-oil-in-water emulsions and methods of use
CN111511362A (en) 2017-12-20 2020-08-07 3M创新有限公司 Oral compositions and methods of use
CN111511348A (en) 2017-12-20 2020-08-07 3M创新有限公司 Oral compositions and methods of use
CN113271909A (en) 2018-12-29 2021-08-17 3M创新有限公司 Oral articles and methods of use
WO2020136620A1 (en) 2018-12-29 2020-07-02 3M Innovative Properties Company Oral articles and methods of use

Also Published As

Publication number Publication date
HUP0100731A2 (en) 2002-05-29
TR200001544T2 (en) 2000-11-21
KR20010032800A (en) 2001-04-25
AU1791599A (en) 1999-06-28
NO20002787D0 (en) 2000-05-31
JP2001525406A (en) 2001-12-11
PL340837A1 (en) 2001-02-26
EE200000321A (en) 2001-08-15
IL136368A0 (en) 2001-06-14
HUP0100731A3 (en) 2002-08-28
SK8442000A3 (en) 2001-01-18
CA2312357A1 (en) 1999-06-17
EP1037889A1 (en) 2000-09-27
CN1284074A (en) 2001-02-14
BR9813378A (en) 2000-10-10
WO1999029686A1 (en) 1999-06-17
SE9704546D0 (en) 1997-12-05

Similar Documents

Publication Publication Date Title
NO20002787L (en) New connections
EE200000320A (en) Novel compounds
SE9704544D0 (en) Novel compounds
NO964700D0 (en) Novel amino acid derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
SE9904505D0 (en) Novel compounds
TR199800077T1 (en) Controlled release paroxetine preparations.
NO984290L (en) Pharmaceutically useful compounds
NO975987D0 (en) 4-Phenylaminothiazole derivatives, process for their preparation and pharmaceutical compositions containing said derivatives
ATE231872T1 (en) THIAZOLOPYRIMIDE DERIVATIVES
AU6617596A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, their preparation process, their use as medicaments, and pharmaceutical compositions containing them
NO971625L (en) Novel peptides with immunomodulatory effects
DK1015421T3 (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals
NO960272L (en) Oxathiolanes, processes for their preparation and pharmaceutical compositions containing the same
NO20001288L (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oils, process for their preparation and use as medicaments
NO20006547L (en) Salts of paroxetine
DK1001942T3 (en) Polyhydroxybutylpyrazines, their preparation, as well as drugs containing these compounds
NO990322L (en) Pharmaceutical mixture containing a 5HT2c antagonist and a D2 antagonist
NO991481L (en) New heteroaryloxyethylamines, process for preparation, use as medicine and pharmaceutical compositions containing these
NO995905D0 (en) New phenocyclidine derivatives, methods of preparation, and pharmaceutical compositions containing them
NO20040471L (en) 5,6,6a, 11b-tetrahydro-7-oxa-5-azabenzo [c] fluorene-6-carboxylic acid derivatives as NMDA antagonists
TR200000916T2 (en) Substituted piperidine derivatives.
NO20075921L (en) Benzimidazole water levels that modulate chemokine receptors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application